Clinical trials information on virus proteome based vaccine design
This page provides additional information to users of the VLCvirus on clinical trial where oncogenic virusess are used, either in live/attenuated/ or in combination with chemotherapy for treatment of lung cancer. By clicking onto clinical trial ID (NCTXXXXX), user will be redirected towards clinical trial page containing all the information regarding disease condition, status etc. For more information see HELP page.
| Lung Cancer Vaccine Plus Oral Dietary Supplement | vaccine 1650-G | NCT01829373 |
| Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer | autologous dendritic cell cancer vaccine | NCT00103116 |
| Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer | Vaccine Treatment|Drug: Cyclophosphamide|Drug: All-trans retinoic acid (ATRA) | NCT00601796 |
| Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy | Ad100-gp96Ig-HLA A1 | NCT00503568 |
| Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Autologous dendritic cell-adenovirus p53 vaccine|Drug: Carboplatin|Drug: Etoposide | NCT00049218 |
| Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid | vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant | NCT01349647 |
| Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer | DRibble vaccine | NCT00850785 |
| Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient | MV mix vaccine|Other: standard treatment | NCT02333474 |
| Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | mutant p53 peptide pulsed dendritic cell vaccine|Procedure: adjuvant therapy | NCT00019929 |
| Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | mutant p53 peptide pulsed dendritic cell vaccine|Procedure: adjuvant therapy | NCT00019929 |